Loading company…
sRNAlytics is a San Francisco biotech developing precision oligonucleotide therapeutics based on small RNA molecules.
Based in San Francisco, US, sRNAlytics is a biotechnology company co-founded by David Salzman and Neal Foster, with David Salzman as CEO. It develops biomarker-guided oligonucleotide therapeutics that target pulmonary, cardiac, neurological and autoimmune diseases, using its Code-Breaker platform, which applies AI to small RNAs. In November 2017 it raised an undisclosed seed round from IndieBio and SOSV. The company plans to expand its therapeutics pipeline and increase its presence in Asia by the end of 2024.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in